About this Research Topic
For the early detection of the potential risk for developing AD, it is imperative to understand and differentiate metabolic and vascular changes between cognitive aging and AD. Neuroimaging methods have been developed as powerful biomarkers for identifying in vivo metabolic and vascular functions. For example, CMRglc and CMRO2 can be determined by PET, and CBF can be measured by both PET and magnetic resonance imaging (MRI). Multi-nuclei magnetic resonance spectroscopy (MRS) can be used to measure bioenergetics in vivo, including oxygen-17 for CMRO2, phosphorus-31 for adenosine triphosphate (ATP), and carbon-13 for for mitochondria oxidative metabolism and neuronal activity. In addition, confocal or multi-photon microscopic imaging have been used to determine BBB integrity and cerebral microinfarcts. All of these state-of-the-art neuroimaging technologies have been applied to study brain aging and AD.
In this Research Topic, we welcome contributions to address the critical needs for developing metabolic and vascular neuroimaging biomarkers for brain aging and AD. We welcome both preclinical and clinical studies with imaging technology including, but not limited to, PET, MRI, MRS, and microscopic imaging. We believe that this series of publications will stimulate conversation and discussion toward the potential prevention of AD, slowing brain aging by protecting metabolic and vascular functions with age, and the potential of using neuroimaging as surrogate markers for the design and determination of effective interventions.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.